Elucidating the cellular mechanism for E2-induced dermal fibrosis

Area of Science:

• Dermatology
• Endocrinology
• Molecular Biology

Background:

• Both transforming growth factor-beta (TGFβ) and estradiol (E2) promote skin fibrosis.
• In systemic sclerosis (SSc), both TGFβ and E2 are implicated in pathogenesis.
• The precise regulation of TGFβ by E2 in dermal fibrosis is not fully understood.

Purpose of the Study:

• To elucidate the regulatory mechanisms of TGFβ in E2-induced dermal fibrosis.
• To identify key proteins and extracellular matrix (ECM) components involved in E2-driven TGFβ signaling.
• To explore potential therapeutic targets for fibrotic diseases.

Main Methods:

• Quantitative PCR (qPCR) was used to measure TGFβ1 and TGFβ2 levels in E2-stimulated human dermal fibroblasts and skin tissue.
• The role of the ERK/MAPK pathway was assessed using the inhibitor U0126.
• TGFβ receptor and estrogen receptor alpha (ERα) signaling were inhibited using SB-431542 and ICI 182,780, respectively, to evaluate their impact on collagen 22A1 (Col22A1) transcription.

Main Results:

• E2 stimulation induced the expression of TGFβ1, TGFβ2, and the TGFβ-responsive gene Col22A1.
• Col22A1 induction was abrogated by inhibiting TGFβ receptors (SB-431542) and ERα (ICI 182,780).
• Inhibition of E2-induced ERK/MAPK activation and early growth response 1 (EGR1) transcription prevented the upregulation of TGFβ1 and TGFβ2.

Conclusions:

• E2-induced dermal fibrosis involves the upregulation of TGFβ1, TGFβ2, and Col22A1.
• This process is regulated by EGR1 and the MAPK pathway.
• Targeting estrogen signaling presents a novel therapeutic avenue for pro-fibrotic conditions.